Advanced search
Publication Cover
Renal Failure Volume 40, 2018 - Issue 1
Submit an article Journal homepage
1,158
Views
8
CrossRef citations to date
0
Altmetric
Clinical Study

The role of mitofilin in left ventricular hypertrophy in hemodialysis patients

Qi-Shun WuDivision of Nephrology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China; View further author information
,
Qing HeDivision of Hemodialysis, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; View further author information
,
Jian-Qiang HeDivision of Nephrology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China; View further author information
,
Jun ChaoDivision of Nephrology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China; View further author information
,
Wen-Yan WangDivision of Nephrology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China; View further author information
,
Yan ZhouDivision of Nephrology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, China; View further author information
,
Ji-Zhuang LouDivision of Hemodialysis, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; View further author information
,
Wei KongDivision of Nephrology, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaView further author information
&
Jun-Feng ChenDivision of Nephrology, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 252-258 | Received 21 Oct 2017, Accepted 15 Mar 2018, Published online: 05 Apr 2018

References

  • Charytan D. Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23:578–585.
  • McCullough PA, Chan CT, Weinhandl ED, et al. Intensive hemodialysis, left ventricular hypertrophy, and cardiovascular disease. Am J Kidney Dis. 2016;68:S5–S14.
  • Oguz EG, Gursoy GK, Yayar O, et al. Increased serum renalase in hemodialysis patients: is it related to left ventricular hypertrophy? Ren Fail. 2016;38:1180–1186.
  • Leibowitz D. Left ventricular hypertrophy and chronic renal insufficiency in the elderly. Cardiorenal Med. 2014;4:168–175.
  • Taddei S, Nami R, Bruno RM, et al. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev. 2011;16:615–620.
  • Icho T, Ikeda T, Matsumoto Y, et al. A novel human gene that is preferentially transcribed in heart muscle. Gene. 1994;144:301–306.
  • Zerbes RM, van der Klei IJ, Veenhuis M, et al. Mitofilin complexes: conserved organizers of mitochondrial membrane architecture. Biol Chem. 2012;393:1247–1261.
  • Park YU, Jeong J, Lee H, et al. Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with mitofilin. Proc Natl Acad Sci USA. 2010;107:17785–17790.
  • Thapa D, Nichols CE, Lewis SE, et al. Transgenic overexpression of mitofilin attenuates diabetes mellitus-associated cardiac and mitochondria dysfunction. J Mol Cell Cardiol. 2015;79:212–223.
  • Yang RF, Zhao GW, Liang ST, et al. Mitofilin regulates cytochrome C release during apoptosis by controlling mitochondrial cristae remodeling. Biochem Biophys Res Commun. 2012;428:93–98.
  • Zhao JR, Zhang DY, Sun DZ. Correlation research on ADMA plasma levels and left ventricular function of peritoneal dialysis patients. Int J Clin Exp Med. 2014;7:4455–4460.
  • Farowski F, Cornely OA, Vehreschild JJ, et al. Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. Int J Antimicrob Agents. 2013;41:379–382.
  • Leifheit-Nestler M, Grosze Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088–1099.
  • Lee YJ, Song BG, Kim MS, et al. Interaction of malnutrition, N-terminal pro-B-type natriuretic peptide and ventricular remodeling in patients on maintenance hemodialysis. Clin Nephrol. 2013;79:253–260.
  • Rebić D, Rašić S, Hamzić-Mehmedbašić A, et al. Valvular calcification and left ventricular modifying in peritoneal dialysis patients. Ren Fail. 2015;37:1316–1322.
  • Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001;76:1111–1119.
  • Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J Cardiol. 2014;6:1091–1099.
  • Pisano A, Cerbelli B, Perli E, et al. Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure. Cardiovasc Pathol. 2016;25:103–112.
  • Rao M, Li L, Demello C, et al. Mitochondrial DNA injury and mortality in hemodialysis patients. J Am Soc Nephrol. 2009;20:189–196.
  • Gamboa JL, Billings FT VI, Bojanowski MT, et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep. 2016;4:e12780. Pii:
  • Suzuki T, Yamaguchi H, Kikusato M, et al. Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. J Am Soc Nephrol. 2016;27:1925–1932.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.